CHOL-ECOL-O

• AGENCE DE LA SANTÉ PUBLIQUE DU CANADA. Déclaration sur la diarrhée du voyageur , [En ligne], 24 avril 2015.
• CLEMENS, J.D., et autres. “Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial”, The Journal of Infectious Diseases, vol. 158, n^o 2, août 1988, p. 372-377.
• HILL, D.R. “Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries ”, [En ligne], The American Journal of Tropical Medicine and Hygiene, vol. 62, no 5, mai 2000, p. 585-589.
• HILL, D.R., et N.J. BEECHING. “Travelers’ diarrhea”, Current Opinion in Infectious Diseases, vol. 23, n^o 5, octobre 2010, p. 481-487.
• JELINEK, T., et H. KOLLARITSCH. “Vaccination with Dukoral^® against travelers’ diarrhea (ETEC) and cholera”, Expert Review of Vaccines, vol. 7, n^o 5, juillet 2008, p. 561-567.
• LÓPEZ-GIGOSOS, R., et autres. “Effectiveness in prevention of travellers’ diarrhoea by an oral cholera vaccine WC/rBS”, Travel Medicine and Infectious Disease, vol. 5, n^o 6, novembre 2007, p. 380-384.
• LUNDKVIST, J., R. STEFFEN et B. JÖNSSON. “Cost-Benefit of WC/rBS Oral Cholera Vaccine for Vaccination Against ETEC-Caused Travelers' Diarrhea ”, [En ligne], Journal of Travel Medicine, vol. 16, no 1, janvier-février 2009, p. 28-34.
• ORGANISATION MONDIALE DE LA SANTÉ. « Vaccins anticholériques : note de synthèse de l’OMS-août 2017 », [En ligne], Relevé épidémiologique hebdomadaire, vol. 92, no 34, 25 août 2017, p. 477-498.
• PELTOLA, H., et autres. “Prevention of travellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine”, The Lancet, vol. 338, n^o 8778, 23 novembre 1991, p. 1285-1289.
• SCERPELLA, E.G., et autres. “Safety, Immunogenicity, and Protective Efficacy of the Whole‑Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers’ Diarrhea ”, [En ligne], Journal of Travel Medicine, vol. 2, no 1, mars 1995, p. 22-27.
• STEFFEN, R., et autres. “Vaccination against Enterotoxigenic Escherichia coli, a Cause of Travelers’ Diarrhea ”, [En ligne], Journal of Travel Medicine, vol. 12, no 2, mars 2005, p. 102-107.
• SVENNERHOLM, A.M., et J. TOBIAS. “Vaccines against enterotoxigenic Escherichia coli”, Expert Review of Vaccines, vol. 7, n^o 6, août 2008, p. 795-804.
• TANVIR, A., et autres. “Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea ”, [En ligne], The Cochrane Library, 5 juillet 2013.
• WEINKE, T., et autres. “Prophylactic immunisation against traveller’s diarrhoea caused by enterotoxin-forming strains of Escherichia coli and against cholera: does it make sense and for whom?”, Travel Medicine and Infectious Disease, vol. 6, n^o 6, novembre 2008, p. 362-367.

EJ

• AGENCE DE LA SANTÉ PUBLIQUE DU CANADA. « Déclaration sur la protection contre l’encéphalite japonaise », [En ligne], Relevé des maladies transmissibles au Canada, vol. 37, DCC-1, avril 2011, p. 1-15.
• CENTERS FOR DISEASE CONTROL AND PREVENTION. “Japanese Encephalitis Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) ”, [En ligne], Morbidity and Mortality Weekly Report : Recommendations and Reports, vol. 59, no RR-1, 12 mars 2010, p. 1-27.
• CENTERS FOR DISEASE CONTROL AND PREVENTION. “Recommendations for Use of a Booster Dose of Inactivated Vero Cell Culture-Derived Japanese Encephalitis Vaccine ”, [En ligne], Morbidity and Mortality Weekly Report: Weekly, vol. 60, no 20; 27 mai 2011, p. 661-663.
• CENTERS FOR DISEASE CONTROL AND PREVENTION. “Use of Japanese Encephalitis Vaccine in Children: Recommendations of the Advisory Committee on Immunization Practices, 2013 ”, [En ligne], Morbidity and Mortality Weekly Report: Weekly, vol. 62, no 45; 15 novembre 2013, p. 898-900.
• DUBISCHAR, K.L., et autres. “Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region ”, [En ligne], The Pediatric Infectious Disease Journal, vol. 36, no 9, septembre 2017, p. 898-904.
• DUBISCHAR, K.L., et autres. “Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study ”, [En ligne], The Pediatric Infectious Disease Journal, vol. 36, no 9, septembre 2017, p. 889-897.
• EDER, S., et autres. “Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO^®, IC51”, Vaccine, vol. 29, n^o 14, 21 mars 2011, p. 2607-2612.
• KALTENBÖCK, A., et autres. “Safety and immunogenicity of concomitant vaccination with the cell‑culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX^® 1440 in healthy subjects: A single‑blind, randomized, controlled Phase 3 study”, Vaccine, vol. 27, n^o 33, 16 juillet 2009, p. 4483‑4489.
• KALTENBÖCK, A., et autres. “Immunogenicity and safety of IXIARO^® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age”, Vaccine, vol. 28, n^o 3, 8 janvier 2010, p. 834‑839.
• ORGANISATION MONDIALE DE LA SANTÉ. « Vaccins contre l’encéphalite japonaise », Relevé épidémiologique hebdomadaire, [En ligne], vol. 81, nos 34-35, 25 août 2006, p. 331-340.
• PAULKE-KORINEK, M., et autres. “Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis”, Vaccine, vol. 33, n^o 30, 9 juillet 2015, p. 3600-3604.
• SCHULLER, E., et autres. “Long‑term immunogenicity of the new Vero cell‑derived, inactivated Japanese encephalitis virus vaccine IC51: Six and 12 month results of a multicenter follow‑up phase 3 study”, Vaccine, vol. 26, n^o 34, 12 août 2008, p. 4382‑4386.
• SCHULLER, E., et autres. “Comparison of a single, high‑dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer‑blind, controlled Phase 3 study”, Vaccine, vol. 27, n^o 15, 26 mars 2009, p. 2188-2193.
• WOOLPERT, T., et autres. “Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain‑derived JE vaccine”, Vaccine, vol. 30, n^o 20, 26 avril 2012, p. 3090-3096.

FJ

• AZEVEDO, L.S., et autres. “Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study ”, [En ligne], Transplant Infectious Disease, vol. 14, no 3, juin 2012, p. 237-241. 
• BAE, H.G., et autres. “Immune Response during Adverse Events after 17D-Derived Yellow Fever Vaccination in Europe ”, [En ligne], The Journal of Infectious Diseases, vol. 197, no 11, 1^er juin 2008, p. 1577-1584. 
• BARRETT, A.D.T., et D.E. TEUWEN. “Yellow fever vaccine — how does it work and why do rare cases of serious adverse events take place?”, Current Opinion in Immunology, vol. 21, n^o 3, juin 2009, p. 308-313.
• BARRETT, A.D.T., et autres. “17D yellow fever vaccines: New insights: A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005”, Vaccine, vol. 25, n^o 15, 12 avril 2007, p. 2758-2765.
• BARWICK EIDEX, R. “History of thymoma and yellow fever vaccination ”, [En ligne], The Lancet, vol. 364, no 9438, 11 septembre 2004, p. 936.
• BELSHER, J.L., et autres. “Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease”, Vaccine, vol. 25, n^o 50, 5 décembre 2007, p. 8480-8485.
• BRUYAND, M., et autres. « Vaccination contre la fièvre jaune en dehors des sujets immunocompétents », Médecine et maladies infectieuses, vol. 38, n^o 10, octobre 2008, p. 524-532.
• CAMACHO, L.A.B., et autres. “Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial ”, [En ligne], Revista de Saúde Pública, vol. 39, no 3, 2005, p. 413‑420.
• CAVALCANTI, D.P., et autres. “Early exposure to yellow fever vaccine during pregnancy ”, [En ligne], Tropical Medicine & International Health, vol. 12, no 7, juillet 2007, p. 833‑837.
• CENTERS FOR DISEASE CONTROL AND PREVENTION. “Fever, Jaundice, and Multiple Organ System Failure Associated With 17D-Derived Yellow Fever Vaccination, 1996–2001”, [En ligne], Morbidity and Mortality Weekly Report: Weekly, vol. 50, no 30, 3 août 2001, p. 643-645.
• CENTERS FOR DISEASE CONTROL AND PREVENTION. “Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) ”, [En ligne], Morbidity and Mortality Weekly Report: Recommendations and Reports, vol. 59, no RR-7, 30 juillet 2010, p. 1-26.
• CHAN, R.C., et autres. “Hepatitis and death following vaccination with 17D-204 yellow fever vaccine”, The Lancet, vol. 358, n^o 9276, 14 juillet 2001, p. 121-122.
• COMITÉ CONSULTATIF DE LA MÉDECINE TROPICALE ET DE LA MÉDECINE DES VOYAGES. Recommandations canadiennes provisoires concernant l’utilisation d’une dose fractionnée du vaccin contre la fièvre jaune durant une pénurie du vaccin , [En ligne], 13 septembre 2017. (Consulté le 29 janvier 2018).
• COMITÉ CONSULTATIF DE LA MÉDECINE TROPICALE ET DE LA MÉDECINE DES VOYAGES. Déclaration sur l’administration d’une dose de rappel du vaccin contre la fièvre jaune , [En ligne], 18 janvier 2018. (Consulté le 29 janvier 2018).
• FAREZ, M.F., et J. CORREALE. “Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis ”, [En ligne], Archives of Neurology, vol. 68, no 10, octobre 2011, p. 1267-1271.
• GERSHMAN, M.D., et autres. “Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data”, Vaccine, vol. 30, n^o 33, 13 juillet 2012, p. 5038-5058.
• GOTUZZO, E. Efficacy and Duration of Immunity Following Yellow Fever Vaccine: A Systematic Review on the Need of Yellow Fever Booster Every 10 Years , [En ligne], 24 p.
• JENTES, E.S., et autres. “The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever”, The Lancet Infectious Diseases, vol. 11, n^o 8, août 2011, p. 622‑632.
• KELSO, J.M., et J.W. YUNGINGER. “Immunization of egg-allergic individuals with egg- or chicken-derived vaccines”, Immunology and Allergy Clinics of North America, vol. 23, n^o 4, novembre 2003, p. 635-648.
• KELSO, J.M., G.T. MOOTREY et T.F. TSAI. “Anaphylaxis from yellow fever vaccine ”, [En ligne], The Journal of Allergy and Clinical Immunology, vol. 103, n° 4, avril 1999, p. 698‑701.
• KELSO, J.M., et autres. “Common allergens in avian meats ”, The Journal of Allergy and Clinical Immunology, [En ligne], vol. 104, no 1, juillet 1999, p. 202-204.
• KHROMAVA, A.Y., et autres. “Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events”, Vaccine, vol. 23, n^o 25, 9 mai 2005, p. 3256-3263.
• KUHN, S., et autres. “Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk ”, [En ligne], Canadian Medical Association Journal, vol. 183, no 4, 8 mars 2011, p. E243-E245.
• LOEBERMAN, M., et autres. “Vaccination against infection in patients with multiple sclerosis”, Nature Reviews: Neurology, vol. 8, n^o 3, mars 2012, p. 143-151.
• MARTIN, M., et autres. “Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination ”, [En ligne], Emerging Infectious Diseases, vol. 7, n° 6, novembre-décembre 2001, p. 945-951.
• MARTINS, R.M., et autres. “Yellow fever vaccination: Some thoughts on how much is enough [Vaccine 23 (2005) 3908–3914]”, Vaccine, vol. 25, n^o 1, 2 janvier 2007, p. 10‑11.
• McMAHON, A.W., et autres. “Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases”, Vaccine, vol. 25, n^o 10, 26 février 2007, p. 1727‑1734.
• MONATH, T.P. “Review of the risks and benefits of yellow fever vaccination including some new analyses”, Expert Review of Vaccines, vol. 11, n^o 4, avril 2012, p. 427-448.
• MOSIMANN, B., et autres. “Yellow fever vaccine and egg allergy ”, The Journal of Allergy and Clinical Immunology, [En ligne], vol. 95, no 5, mai 1995, p. 1064.
• NASIDI, A., et autres. “Yellow fever vaccination and pregnancy: a four-year prospective study”, The Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 87, n^o 3, mai-juin 1993, p. 337-339.
• NISHIOKA, S.D.A., et autres. “Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study ”, Tropical Medicine & International Health, [En ligne], vol. 3, no 1, janvier 1998, p. 29-33.
• ORGANISATION MONDIALE DE LA SANTÉ. « Note de synthèse : position de l’OMS sur les vaccins et la vaccination contre la fièvre jaune, juin 2013  », [En ligne], Relevé épidémiologique hebdomadaire, vol. 88, no 27, 5 juillet 2013, p. 269-283.
• ORGANISATION MONDIALE DE LA SANTÉ. Fièvre jaune : Aide-mémoire  no 100, [En ligne], juin 2016. (Consulté le 29 janvier 2018).
• PACANOWSKI, J., et autres. “Plasma HIV-RNA Is the Key Determinant of Long-Term Antibody Persistence After Yellow Fever Immunization in a Cohort of 364 HIV-Infected Patients ”, [En ligne], Journal of Acquired Immune Deficiency Syndromes, vol. 59, no 4, 1^er avril 2012, p. 360‑367.
• POLAND, J.D., et autres. “Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine ”, [En ligne], Bulletin of the World Health Organization, vol. 59, no 6, 1981,  p. 895-900.
• QUEREC, T.D., et B. PULENDRAN. “Understanding the role of innate immunity in the mechanism of action of the live attenuated yellow fever vaccine 17D”, Advances in Experimental Medicine and Biology, vol. 590, 2007, p. 43-53.
• RECEVEUR, M.C., et autres. “Yellow Fever Vaccination of Human Immunodeficiency Virus‑Infected Patients: Report of 2 Cases ”, [En ligne], Clinical Infectious Diseases, vol. 31, no 3, septembre 2000, p. e7-e8.
• ROBERT, E., et autres. “Exposure to yellow fever vaccine in early pregnancy”, Vaccine, vol. 17, n^o 3, février 1999, p. 283-285.
• ROUKENS, A.H., et autres. “Elderly Subjects Have a Delayed Antibody Response and Prolonged Viraemia following Yellow Fever Vaccination: A Prospective Controlled Cohort Study ”, PLOS ONE, [En ligne], 7 décembre 2011.
• SIDIBE, M., et autres. “Immunogenicity and safety of yellow fever vaccine among 115 HIV‑infected patients after a preventive immunisation campaign in Mali”, The Transactions of the Royal Society of Tropical Medicine & Hygiene, vol. 106, n^o 7, juillet 2012, p. 437-444.
• SUZANO, C.E.S., et autres. “The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil”, Vaccine, vol. 24, n^o 9, 27 février 2006, p. 1421-1426.
• THOMAS, R.E., et autres. “Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review”, Vaccine, vol. 29, n^o 28, 20 juin 2011, p. 4544-4555.
• THOMAS, R.E., et autres. “Reporting rates of yellow fever vaccine 17D or 17DD‑associated serious adverse events in pharmacovigilance data bases: systematic review”, Current Drug Safety, vol. 6, n^o 3, juillet 2011, p. 145-154.
• THOMAS, R.E., et autres. “The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: Systematic review”, The American Journal of Tropical Medicine and Hygiene, vol. 86, n^o 2, février 2012, p. 359‑372.
• TRAIBER, C., et autres. “Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk”, Jornal de Pediatria, vol. 87, n^o 3, mai-juin 2011, p. 269‑272.
• TSAI, T.F., et autres. “Congenital Yellow Fever Virus Infection after Immunization in Pregnancy”, The Journal of Infectious Diseases, vol. 168, n^o 6, décembre 1993, p. 1520‑1523.
• VASCONCELOS, P.F.C., et autres. “Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases”, The Lancet, vol. 358, n^o 9276, 14 juillet 2001, p. 91-97.
• Veit, O., et autres. “Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‑Infected Patients ”, [En ligne], Clinical Infectious Diseases, vol. 48, no 5, 1^er mars 2009, p. 659-666.
• WYPLOSZ, B., et autres. « Vaccination du voyageur adulte transplanté d’organes (à l’exclusion des receveurs de cellules souches hématopoïétiques », Médecine et maladies infectieuses, vol. 39, n^o 4, avril 2009, p. 225-233.

HA-TYPH-I

• BEECHING, N.J., et autres. “Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults”, Vaccine, vol. 23, n^o 1, 15 novembre 2004, p. 29-35.
• BERAN, J., R. CHLIBEK et F. WEBER. “A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults”, Vaccine, vol. 21, n^o 32, 1^er décembre 2003, p. 4650-4654.
• EKWALL, E., et autres. “Interchangeability of hepatitis A boosters, Avaxim^® and Vaqta^®, in healthy adults following a primary dose of the combined typhoid/Hepatitis A vaccine Viatim^®”, Vaccine, vol. 24, n^o 20, 15 mai 2006, p. 4450-4457.
• LOEBERMANN, M., et autres. “A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults”, Clinical Therapeutics, vol. 26, n^o 7, juillet 2004, p. 1084-1091.
• OVERBOSCH, D., et autres. “Combined Typhoid Fever and Hepatitis A Vaccine: Comparison of Immunogenicity and Safety to Concomitant Monovalent Vaccine over 3 Years ”, [En ligne], Journal of Travel Medicinevol. 12, no 6, novembre 2005, p. 319-326.
• VAN HOECKE, C., et autres. “Concomitant Vaccination against Hepatitis A and Typhoid Fever ”, [En ligne], Journal of Travel Medicine, vol. 5, no 3, septembre 1998, p. 116-120.

TYPH-I ET TYPH-O

• AGENCE DE LA SANTÉ PUBLIQUE DU CANADA. Déclaration concernant les voyageurs internationaux et la typhoïde , [En ligne], 2014, 51 p.
• ANWAR, E., et autres. “Vaccines for preventing typhoid fever ”, [En ligne], The Cochrane Library, 2 janvier 2014.
• CENTERS FOR DISEASE CONTROL AND PREVENTION. “Updated Recommendations for the Use of Typhoid Vaccine — Advisory Committee on Immunization Practices, United States, 2015 ”, [En ligne], Morbidity and Mortality Weekly Report: Weekly, vol. 64, n° 11, 27 mars 2015, p. 305-308.
• CRYZ, S.J. “Patient Compliance in the Use of Vivotif Berna® Vaccine, Typhoid Vaccine, Live Oral Ty21a ”, [En ligne], Journal of Travel Medicine, vol. 5, no 1, mars 1998, p. 14-17.
• ENGELS, E.A., et autres. “Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity ”, [En ligne], British Medical Journal, vol. 316, no 7125, 10 janvier 1998, p. 110-116.
• FAUCHER, J.F., et autres. “Efficacy of Atovaquone/Proguanil for Malaria Prophylaxis in Children and Its Effect on the Immunogenicity of Live Oral Typhoid and Cholera Vaccines ”, [En ligne], Clinical Infectious Diseases, vol. 35, no 10, 15 novembre 2002, p. 1147-1154.
• FERRECCIO, C., et autres. “Comparative Efficacy of Two, Three, or Four Doses of Ty21a Live Oral Typhoid Vaccine in Enteric-Coated Capsules: A Field Trial in an Endemic Area”, The Journal of Infectious Diseases, vol. 159, n° 4, avril 1989, p. 766-769.
• FRASER, A., et autres. “Typhoid fever vaccines: Systematic review and meta-analysis of randomised controlled trials”, Vaccine, vol. 25, n^o 45, 7 novembre 2007, p. 7848-7857.
• FROESCHLE, J.E., et M.D. DECKER. “Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever”, Vaccine, vol. 28, n^o 6, 10 février 2010, p. 1451-1453.
• KOLLARITSCH, H., et autres. “Safety and Immunogenicity of Live Oral Cholera and Typhoid Vaccines Administered Alone or in Combination with Antimalarial Drugs, Oral Polio Vaccine, or Yellow Fever Vaccine”, The Journal of Infectious Diseases, vol. 175, n^o 4, avril 1997, p. 871-875.
• LEVINE, M.M., et autres. “Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine”, Vaccine, vol. 17, suppl. 2, octobre 1999, p. S22-S27.
• MARCUS, L.C., et autres. “Safety of Typhim Vi Vaccine in a Postmarketing Observational Study ”, [En ligne], Journal of Travel Medicine, vol. 14, n° 6, novembre-décembre 2007, p. 386-391.
• ORGANISATION MONDIALE DE LA SANTÉ. « Vaccins antityphoïdiques : note d’information de l’OMS  », Relevé épidémiologique hebdomadaire, [En ligne], vol. 83, no 6, 8 février 2008, p. 49-59.